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Abstract
Background: The Influenza A H1N1 virus can be transmitted via direct, indirect, and airborne route to non-infected
subjects when an infected patient coughs, which expels a number of different sized droplets to the surrounding
environment as an aerosol. The objective of the current study was to characterize the human cough aerosol
pattern with the aim of developing a standard human cough bioaerosol model for Influenza Pandemic control.
Method: 45 healthy non-smokers participated in the open bench study by giving their best effort cough. A laser
diffraction system was used to obtain accurate, time-dependent, quantitative measurements of the size and
number of droplets expelled by the cough aerosol.
Results: Voluntary coughs generated droplets ranging from 0.1 - 900 microns in size. Droplets of less than one-
micron size represent 97% of the total number of measured droplets contained in the cough aerosol. Age, sex,
weight, height and corporal mass have no statistically significant effect on the aerosol composition in terms of size
and number of droplets.
Conclusions: We have developed a standard human cough aerosol model. We have quantitatively characterized
the pattern, size, and number of droplets present in the most important mode of person-to-person transmission of
IRD: the cough bioaerosol. Small size droplets (< 1 μm) predominated the total number of droplets expelled when
coughing. The cough aerosol is the single source of direct, indirect and/or airborne transmission of respiratory
infections like the Influenza A H1N1 virus.
Study design: Open bench, Observational, Cough, Aerosol study
Background
Since the early 1990s the World Health Organization
(WHO), along with other governmental and non-gov-
ernmental agencies, has issued multiple requests to the
scientific community. These requests have been for con-
tributions in the development and design of novel
approaches, methods, and technologies to optimize
management of infectious respiratory diseases (IRD) in
anticipation of new and re-emerging transmissible
respiratory diseases, such as the Influenza Pandemic and
Tuberculosis (TB).
The WHO reported that around one third of the
world’s population are carriers of Mycobacterium tuber-
culosis, the bacillus that leads to active TB. Annually,
nine (9) million new cases of active TB are reported
around the world in young and middle aged adults, with
about 1.7 million deaths in 2009.
Currently, the Influenza Pandemic Preparedness Plan
developed by the WHO considers vaccination as the
main support to prevent disease and death from epi-
demic-prone and pandemic-prone IRD, anti viral are
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around the world have adopted this plan.
Textbooks in Medicine and in other health related
areas teach that infectious respiratory diseases such as
Tuberculosis and Influenza have a common symptom:
cough. Those textbooks also teach that via cough is how
these diseases are spread and transmitted to non-
infected susceptible individuals. Cough mechanisms are
described in those textbooks with emphasis in clinical
diagnostic and management of the individual with
cough [7-9].
Public Health authorities promote and recommend
simple non-pharmacological interventions (NPI), such as
hand washing, respiratory hygiene/cough etiquette, face-
masks, school closures, and social distancing or isolation
to prevent transmission of droplet-spread epidemic-
prone diseases. However, researchers like Morse, con-
sider that most of these NPI are based on weak scienti-
fic evidence [10]. Moreover, the unexpected outbreak of
the severe acute respiratory syndrome caused by a coro-
navirus (SARS-CoV) [11], together with the outbreak of
the highly pathogenic avian influenza H5N1 virus
(2005), brought to the forefront the need to find new
and more effective IRD transmission control measures
[12-16].
IRD are a leading cause of morbidity and mortality in
humans. They cause great disruptions in many sectors -
economic, educational, recreational, and familial - and
can bring worldwide healthcare systems to near collapse.
IRD, whether bacterial, mycotic or viral, are transmitted
to non-infected persons when an infected individual
expels droplets loaded with pathogenic microorganisms
during coughing.
There are three components required for the trans-
mission of any respiratory pathogen: a) the transmissor
(infected person), b) the surrounding environment, and
c) the recipient (non-infected person). Some additional
considerations include the concentration of infectious
droplets determined by the volume of the space and its
ventilation, the length of time of exposure, as well as
the status of defense mechanisms of the exposed
individual.
Regarding the transmission of IRD, there are many
widely accepted facts: a) IRD are transmitted via droplets
originating in the respiratory system of an infected indivi-
dual, b) non-infected individuals could be infected via
direct, indirect and/or airborne route, c) infection could
occur at a very short distance but also at a very long dis-
tance, and d) cough is the most representative source of
droplets expelled as aerosol. Consequently, viruses such
as Influenza A H1N1 are transmitted when an infected
patient expels droplets of different sizes loaded with
pathogenic microorganisms, to the surrounding environ-
ment as an aerosol during coughing [17-22].
Despite these facts, there is still an ongoing debate to
determine whether the transmission of influenza from
person to person occurs either primarily through inhal-
ing micron-sized droplets (an airborne route), or
through direct or indirect contact with larger sized dro-
plets (physical contact route).
The end result of this debate will have a direct influ-
ence on social distancing (i.e. how far apart people
should position themselves to prevent infection) and on
whether current recommended primary prevention mea-
sures and commonly used personal protective equip-
ment are effective barriers to transmission.
What is clear is that the influenza virus requires a
mucosa as the entry point to the body. The most vul-
nerable areas include the mucosa of the eyes, mouth,
throat, and the vast surface area of the upper and lower
airways and lung tissue. Droplets less than 2.5 microns
dry quickly, remain airborne, and reach deep into the
l u n g sw h e ni n h a l e d .O nt h eo t h e rh a n d ,l a r g e - s i z ed r o -
plets are propelled into the environment during cough-
ing and land on nearby surfaces, potentially becoming a
source of transmission when standard and/or contact
precautions are not followed as recommended.
The unexpected emergence of the H1N1 virus, that
triggered two waves of pandemic Influenza A in 2009
[23], confirmed the need to close those important gaps
in knowledge regarding the routes of transmission of
droplet-spread diseases as well as to optimize NPI.
Coughing is the second most important mechanism,
after mucociliary action, in the clearance of respiratory
secretions, as well as the most common symptom of
many infectious and non-infectious respiratory diseases.
In this article we adhere to definition of cough provided
by the European Respiratory Society (ERS): Cough is a
three-phase expulsive motor act characterized by an
inspiratory effort (inspiratory phase), followed by a forced
expiratory effort against a closed glottis (compressive
phase) and then by opening of the glottis and rapid
expiratory airflow (expulsive phase) [24].
Therefore, acquiring a deeper insight into airway droplet
break up and dispersion during coughing will be invalu-
able for designing sound evidence-based preventative mea-
sures and practices. This will complement and enhance
protection to the general public, first responders, and
frontline health care workers when caring for and trans-
porting patients to and from healthcare institutions.
Mucus performs an essential role in maintaining a steady
and strictly controlled homeostasis in several systems of
the body, including the respiratory system. Mucus is a
dynamic vehicle with a complex biochemical composition,
capable of exerting unique physical properties. Viscosity
and elasticity are the physical characteristics considered
essential to mucus function, in addition to other important
characteristics, such as adhesivity and spinnability.
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ways: ciliary clearance and cough clearance. Low fre-
quency or low amplitude is closely related to ciliary
clearance, while high frequency/high amplitude is more
closely related to cough clearance. This bimodal
response of the mucus to different frequencies is better
explained with a simple and practical analogy: the seat
belt. The seat belt responds or functions differently
depending on the impulse or tension that is applied. If
one pulls it slowly (low frequency), it can be extended
easily, but if it is pulled suddenly (high frequency), it
holds one tightly to the seat and cannot be extended.
Coughing causes both mucus aerosolization and dro-
plet generation. When the layer of mucus lining the air-
ways interacts with the high-speed airflow of the
expulsive phase (up to100 km/h) [25,26] droplets of dif-
ferent sizes are formed and forced up the airway tree,
during which droplet collision and coalescing may
occur. Hence, droplets coming out of the mouth of a
coughing individual will very likely be a mixture of var-
ious sizes, generated at different levels of the respiratory
systems, and of diverse compositions.
Despite what is known, a large and critical knowledge
gap was encountered when no characterization of a
cough aerosol model in humans or in animals was
found in the literature searched. Other than the general
suggestion to “cover your mouth when coughing“ or to
voluntarily quarantine yourself (i.e. “if you have flu
symptoms, please delay your visit“), we found no evi-
dence-based information on procedures or techniques
regarding cough aerosol control at the source, the
respiratory system of an infected individual.
Previous attempts by Zayas et al. to develop a mam-
malian cough aerosol model yielded no success (2007,
non-published data). This prompted us to strive for the
development of a human cough aerosol model, as well
as to enhance our knowledge and understanding on the
bioaerosol pattern during coughing.
Our main objective was to develop a standard human
cough aerosol model to acquire deeper knowledge and
understanding of the human bioaerosol pattern to best
characterize the number and/or size of droplet produc-
tion contained in the cough aerosol. To achieve this we
required a fast acquisition and high-resolution system,
the laser diffraction technique, to capture the cough
droplet size and number distribution to overcome the
limitation of velocity and evaporation.
Since Duguid [27], (1946) examined the droplet size
distribution using direct micrometry on oiled glass
slides, droplet size technology has evolved to different
instruments, including: optical droplet counter (Fairchild
1987; Papineni 1997; Edwards 2004; Schwarz 2010),
aerodynamic droplet sizer (Yang 2007, Morawska 2009),
scanning mobility droplet sizer (Yang 2007), electrical
low pressure impactor (Hersen 2008), interferometric
Mie imaging (Chao 2009), droplet image velocimetry
(Chao 2009), and laser diffraction system (Edwards
2004). All these previously used measurement techni-
ques have either limited resolution in the submicron
range, or have bias due to sampling air stream. Tang et
al. (2009) have obtained a qualitative real-time charac-
terization of the cough aerosol in human volunteers
using an optical technique known as Schlieren [27-37].
Our goal is to enhance the knowledge on cough
bioaerosol, regarded as the source of direct, indirect
and/or airborne respiratory disease transmission, to
develop a cough aerosol model in humans, and to set
the stage for future studies that will apply novel inter-
ventions to reduce the aerosolizability of respiratory
secretions as a surrogate of transmissibility.
Methods
Study design
This was an observational study in which all the partici-
pants, in an open bench format, were encouraged to
give their best effort to voluntarily elicit a “real cough”
three separate times.
Participants
A total of 45 healthy non-smokers, male/female volun-
teers 18 years of age or older, consented to participate.
Participants were recruited through advertised leaflets in
public areas around a university campus and none of
them declared to having asthma, Cystic Fibrosis, or
other respiratory conditions. Eligible participants were
excluded if they had received expectorants, mucolytics
or natural products for respiratory conditions during the
previous 30 days, or had developed a flu-like illness
immediately before the study.
Study site
The study was carried out at the Mucophysiology
Laboratory, 173 Heritage Medical Research Centre, Uni-
versity of Alberta, Edmonton, Alberta, Canada.
E n v i r o n m e n t a lc o n d i t i o n sa tt h es t u d ys i t ew e r es i m i -
lar to the indoor conditions found in a hospital recep-
tion site with respect to room temperature, humidity
and atmospheric pressure.
The University of Alberta Hospital Medical Ethics Com-
mittee and the Office of Environmental Health and Safety
of the University of Alberta approved the study protocol.
Informed consent was obtained from all subjects.
Study day
The study procedures were explained in detail to all par-
ticipants by the investigator. Once they had understood
the study requirements, all participants were asked to
sign an informed consent.
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For accurate, time-dependent droplet size distribution
analysis, a laser diffraction system (Spraytec, Malvern,
UK) was used. The laser diffraction system has 60 size
bins with the capability of measuring the concentration
of droplet sizes from 0.1 micron (μm) to 900 μme v e r y
0.4 millisecond.
The Spraytec He-Ne (Helium-Neon) laser diffract-
ometer is composed of transmitter and receiver mod-
ules. Expelled respiratory aerosols pass through a
cylindrical measurement zone with a volume of 7.85
cm
3 through a path of 100 mm length and 10 mm dia-
meter. The path length is estimated as the distance
through the spray plume that the laser beam travels. As
the droplets pass through the laser measurement volume
zone, laser light from the transmitter is scattered by the
respiratory aerosol producing light diffraction patterns,
which are measured by optical detectors on the receiver
modules. The light signals are then converted into elec-
trical signals to process a droplet size distribution,
under the assumption that each droplet is a perfect
sphere. The angle at which a droplet diffracts light is
inversely proportional to its size.
The He-Ne laser diffractometer was set to measure
the droplet concentration of a single cough event cross-
ing the measurement zone every 0.4 milliseconds (2.5
GHz) during a manually triggered time of 1.5 seconds.
Statistical analysis
The data were expressed as mean ± standard deviation
(SD) unless otherwise stated. Fulfillment of normal log
distribution was asserted by the Shapiro-Francia test
[38]. A paired Student T-test was used for simple com-
parison. For multiple comparisons between groups a
two-way ANOVA test was used. A value of p < 0.05 was
considered significant.
Research procedures
Cough aerosol
Participants were asked to place their head in a modified
device similar to the head brace used by optometrists
and were asked to perform a “real cough”.T oa s s e s st h e
cough maneuver a laser beam was directed from left to
right in front of and parallel to the participant’s face, at
approximately 17 cm distance from their mouth to the
centre of the beam’s measurement zone. Since there was
no precedents regarding the use of a laser beam in an
open bench format to assess cough aerosol, the 17 cm
distance was a decision made by the researchers. This
decision was based mainly on the grounds of safety: to
avoid contact of the laser beam with the eye or face of
t h ep a r t i c i p a n t .T h e yw e r ep o s i t i o n e dt oa l l o wt h e
cough airflow jet to cross the beam without any interfer-
ence to the flow of the aerosol as seen below (Figure 1).
Opposite to the participants an open fume hood
removed airborne particles from the environment. We
did not measure evaporation rate. Deposition was not a
factor in the open bench design.
Results
During the period of study, March - May 2010, we
detected inside the testing site an average in atmo-
spheric pressure of 91.8 ± 1.1 KPa, in relative humidity
of 19.0 ± 3.9% RH, and in temperature of 22.7 ± 2.0°C.
The rate of air exchange in the study site (six to nine
air exchanges per hour) was lower than in a hospital
emergency room.
Aerosol droplets expelled during a single cough event
were assessed in 26 male and 19 female participants
self-identified as non-smokers, with the exception of
one male who declared he was a long-term (30+ years)
ex-smoker.
Every participant was encouraged to voluntarily elicit a
“real cough” three times. If during the performance
researchers considered that the participant did not make
an adequate effort the participant was ask to repeat the
maneuver until getting an acceptable effort.
In addition to the acceptable cough efforts, we consis-
tently selected three parameters provided by the laser
beam machine: valid points, skip values and total mass
per maneuver. From these parameters we decided and
selected which maneuver was the best. The design
implemented in our study was based similarly to when
performing a spirometry test: three efforts and select the
best effort made. This is a procedure in lung mechanics
very well establish and accepted worldwide.
Full and detailed results were obtained in less than
five minutes after coughing. The average and standard
deviation of weight, height, Body Mass Index (BMI) and
age of all participants is shown in Table 1.
Figure 1 Laser and sensor arrangement for Cough Aerosol
detection.
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height and corporal mass against number and diameter
of droplets, including the value of r and p value.
The average mass of the cough aerosol that crossed
the measurement volume zone, derived from the aerosol
volume concentration, was 2.2 milligrams (mg) for the
45 participants. The cough expulsion phase lasted an
average 700 milliseconds.
The large number of different sized droplets, gener-
ated by the best-effort cough and detected in the 60
bins by the laser diffractometer, were normalized and
expressed as the average rate of number of droplets per
cubic centimeter per second. These averages were
grouped into six (6) categories: a) < 0.5 μm, b) 0.5 to 1
μm, c) > 1.0 to 2.5 μm, d) > 2.5 to 10 μm, e) > 10 to
100 μma n df )>1 0 0μm; then tabulated by age and sex
(Table 3) and summarized in Table 4.
Data obtained from the cough maneuvers in 44 parti-
cipants (outlier removed) showed a large variability in
the number of droplets in all droplet size categories and
the standard deviation was very large.
Acquired data indicates that 97% of droplets, expelled
in one second during coughing, are smaller than 1 μm,
2.7% of droplets are between 1 - 10 μm. Hence, our
data indicates that 99% of the total of droplets expelled,
when a healthy non-smoker coughs, are droplets smaller
than 10 μm, i.e. inhalable droplets.
Participants were categorized as low emitters/high
emitters if their data was one standard deviation below/
higher than the average of the population. Seven (7) par-
ticipants were identified as low emitters, and ten (10) as
high emitters. One ex-smoker (30 + years) was identified
as a high emitter. Another high emitter (> 50 years old)
was beyond two standard deviations greater than the
average and considered an outlier.
T h eo u t l i e ri sav e r yf i ta t h l e t ew h op r a c t i c e sh i g h
intensity sports. The mass of the cough aerosol of the
athlete outlier amounts to 32 mg, compared to the aver-
age of 2.2 mg. When removing the outlier from the rest
of participants, the tabulated data showed very similar
data to the other two age groups as seen in Table 4. Data
presented from now on will be with the outlier removed.
Accounting for more than 97% of the total number of
droplets per cough, droplets smaller than 1 micron were
the most numerous of all. Cough produces a larger
number of droplets per second in every droplet size
category; see Figure 2 below.
Due to the enormous amount of droplets of smaller dia-
meter, columns representing the larger droplet diameters
did not show up in the graph. While it seems that no dro-
plets were detected in the higher ranges, there were in fact
a few droplets (e.g. 63 μm = 42 droplets, 86 μm = 14 dro-
plets, 100 μm=7d r o p l e t s ,2 9 3μm=1d r o p l e t ) .
Figure 3 represents 97% of all droplets measured. In
Figures 3.1 - 3.4 (found in Additional file 1) we show
t h ee n t i r es p e c t r u mo fd r o p l e t sp e rs i z ei na l lb i n s ,
expelled as aerosol when coughing.
Detailed characterizations for the remaining droplet
size categories are included as appendices. Detection of
emitted droplets during cough lasts about 700 millise-
conds and has a tri-modal distribution.
We performed a two-way analysis of variance
(ANOVA) on the data per each category of droplet size
per age and per sex, with and without the outlier. Table 5
shows the ANOVA tests for the < 0.5 μm droplet size.
Table 1 Anthropometric data of 45 participants
n = 45 Weight (kg) Height (cm) BMI (kg/m^2) Age
Average ± SD 66.4 ± 12.9 167.9 ± 9.1 23.5 ± 4.0 34.3 ± 15.2
Table 2 Coefficient Correlation data weight, height and
BMI
n = 45 Weight Height BMI
Average Diameter
r -0.14 -0.05 -0.13
p-value 0.36 0.74 0.39
Number
r 0.24 0.20 0.13
p-value 0.11 0.19 0.39
All participants (n = 45)
Table 3 Average rate of cough droplet size by sex and age
N = 45 Age ≤ 30 30 > Age ≤ 50 Age > 50
Sex Male Female Male Female Male Female
N < 0.5 μm 1.33E+07 5.32E+06 5.27E+06 1.75E+07 4.53E+07 1.65E+07
0.5 μm < N < 1.0 μm 1.89E+05 2.46E+05 1.83E+05 4.06E+05 2.79E+05 2.25E+05
1.0 μm < N < 2.5 μm 3.45E+04 1.12E+04 1.81E+04 4.22E+04 2.69E+04 3.95E+04
2.5 μm < N < 10.0 μm 4.01E+04 1.24E+04 1.78E+04 4.75E+04 4.41E+04 4.51E+04
10 μm < N < 100 μm 1.86E+03 4.95E+02 7.71E+02 3.30E+03 3.46E+03 2.71E+03
N > 100 μm 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00 0.00E+00
Unit: # droplets/cc/second
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categories are included as appendixes.
Discussion
The emphasis of this study was on the development and
refinement of a cough aerosol model in healthy human
volunteers, detected and verified with a laser diffraction
system.
Major findings in this study include: a) the respiratory
system generates droplets of many different sizes during
coughing; b) droplets smaller than ten-microns account
for up to 99% of the total number of droplets that are
expelled as a bioaerosol during coughing; c) due to its
size distribution and amount, the cough bioaerosol has
the potential to contribute directly, indirectly and/or
through airborne route to the transmission of respira-
tory infections, including Influenza A caused by the
H1N1 virus; d) age, sex, weight, height and corporal
mass have no effect on the size and number of emitted
droplets; e) our approach has the potential to identify
high emitters and/or outliers; f) these results create a
foundation for the development of a standardized
human cough aerosol model; g) the acquired data cre-
ates a foundation for the development of tools in airway
hygiene for secretion management, as well as in preven-
tion of droplet-spread illnesses.
During the preparatory phase of this study, our research
group was concerned that healthy non-smokers would
find it difficult to voluntarily perform a reproducible
“near-real-cough aerosol“. We considered requesting parti-
cipants to undergo respiratory challenges such as inhaling
hypertonic saline to induce augmented airway secretion
and/or capsaicin to elicit a “real cough”. The concern was
due to technical facts: the thickness of the airway mucus
layer in healthy non-smokers is 5 to 10 microns [39,40].
The International Organization for Standardization
(ISO) has stated “the laser diffraction technique has
evolved such that it is now a dominant method for deter-
mination of droplet size distribution”.( I S O1 3 3 2 0 : 2 0 0 9
(E) 2009) [41]. While testing and tuning the laser dif-
fraction system we found that our initial concerns were
inaccurate: Healthy non-smokers are excellent models
to characterize cough aerosol droplets. Thus, we avoided
using any challenging intervention that could alter the
physical properties of the airway mucus layer.
The first limitation of this study was that the laser dif-
fraction system, according to the manufacturer, was not
intended to assess aerosolized mucus from the airways
when coughing. This created an uncertainty as to
whether we could capture any droplets at all. However,
thanks to some unique technical expertise in our group,
our lab was able to use the machine for our intended
purposes, if slightly limited.
Table 4 Average rate of cough droplet size by age group
(outlier removed)
N = 44 Age ≤ 30 30 > Age ≤ 50 Age > 50
Exclude outlier
N < 0.5 μm 1.02E+07 1.05E+07 2.89E+07
0.5 μm < N < 1.0 μm 2.15E+05 2.78E+05 2.48E+05
1.0 μm < N < 2.5 μm 2.58E+04 2.84E+04 3.41E+04
2.5 μm < N < 10.0 μm 2.96E+04 3.05E+04 4.47E+04
10 μm < N < 100 μm 1.34E+03 1.85E+03 3.03E+03
N > 100 μm0 0 0
Unit: # droplets/cc/second
Figure 2 Full spectrum characterization of cough aerosol
number versus droplets diameter per second.
Figure 3 Quantities of measured droplets in size category
<1μm per second.
Table 5 Two-way ANOVA results after removing the
“outlier”
N < 0.5 μm
Source Sum Sq. d.f. Mean Sq. F Prob > F
AGE 2.53E+15 2 1.27E+15 2.36 0.11
GENDER 5.66E+14 1 5.66E+14 1.05 0.31
AGE*GENDER 2.04E+15 2 1.02E+15 1.90 0.16
Error 2.04E+16 38 5.37E+14
Total 2.47E+16 43
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the laser diffraction systemw i t haf l u i dt h a th a so p t i c a l
properties different than water. Berge and Pearce report
that the Refraction Index of Air is 1:0 and of Water is:
1.3, and Reid reports that the refractive index of mucus
is very similar to that of pure water [42,43].
Properties of mucus are different in health than dur-
ing disease. Mucus in healthy individuals is more opa-
que than water. In diseased state, mucus opaqueness
could be more pronounced further affecting optical
properties. During bacterial infection there is formation
of pus or mucus could become bloody, altering most
physical and optical properties.
However, during acute viral respiratory infections such
as flu-like diseases, respiratory secretions are watery and
clear. Therefore our assumption is valid for influenza,
SARS-CoV, and avian influenza, which remain our prior-
ity. To assess cough aerosol in diseases like Tuberculosis,
Cystic Fibrosis or others caused by bacteria, we may need
to determine the optical properties of diseased mucus first.
Any droplets travelling in the periphery of the plume
and outside of the measurement zone are unaccounted
for. Our experiment was designed to capture a represen-
tative section of the cough plume crossing the path
length and the measurement zone, including droplets
from the lateral periphery that cross the measurement
section. We estimate that we captured a sample of 15%
of cough droplets that are representative of the cough
plume but we have no definitive way or method to
accurately determine this yet.
There is a confounder we have not deal with yet, and
is the contribution of saliva to the number and size of
droplets detected. This is a topic for the next trials.
Linear correlation indicates a very weak association
between height, weight and BMI with the size and num-
ber of cough droplets expelled. These findings lend
further support to the concept that cough droplet dia-
meter/number distribution is mainly determined by the
physical properties of the layer of mucus, such as elasti-
city, cohesiveness. A mucus layer with low elasticity and
poor cohesiveness due to infections (i.e. the watery
mucus layer during a flu-like disease) or mucus exposed
to respiratory agents that disrupt bondings tends to
break apart with more ease. Consequently, this will form
a larger number of droplets of different size.
A mucus layer with strengthened elasticity and high
cohesiveness will be more resistant to break, and will
form less number of droplets and/or produce fewer dro-
plets of a larger size. This is a concept we described in
previous publications [44,45].
In healthy non-smoker individuals there is an opti-
mum range among their mucus physical properties that
allow it to behave in a balanced manner even at differ-
ent frequencies. This enabled us to reach a milestone:
enhance our understanding of the cough aerosol role in
droplet-spread, pandemic-prone IRD.
Nevertheless, several factors observed in our design
suggested that the “best effort” cough requires improve-
ments. Specifically, the distance from the mouth to the
laser beam and the position of the face, were identified
as factors to further assess and improve in order to
minimize the variability of the acquired data.
The open bench design was selected since we were
interested in characterizing the cough bioaerosol in an
indoor environment that could simulate and explain
what would happen in a real-life emergency room, triage
site, school, home, or any enclosed location where people
gather. This approach would facilitate assessing the char-
acterization of the bioaerosol coming out the respiratory
system and dispersed into the surrounding environment.
Indoor conditions in the study site were maintained at
similar room temperature, humidity, and atmospheric
pressure as in the reception site of a hospital, with the
exception of a lower rate of air exchange. Hence, the
open bench format will not require a translation into
real-life situations, unlike enclosed formats. It took our
group a great deal of effort to overcome the limitation
of the system and extract the number of droplets in the
cough bioaerosol, since the laser diffraction system does
not explicitly provide it. We have not encountered any
information of any research team assessing cough dro-
plets using an open bench format.
Researchers from various disciplines around the globe
have dedicated a large number of studies to the investi-
gation of cough aerosol droplets, using a variety of study
designs, as well as multiple quantitative and qualitative
methods and techniques. During our brief literature
review, we found several key differences between those
studies and our methods: they all used closed systems of
various designs to assess the respiratory droplets; the
majority of them used equipment with much lower
resolution, limited range of sizes and biased droplet col-
lection to characterize the size and number of droplets;
and almost all of them used equipment with much
lower data acquisition speeds than the one used in our
study [27-37]. Without a doubt, these differences played
a critical role in explaining why our data differs from
the majority of data reported in the literature.
Furthermore, our research group considers that it is
fundamental to reach a consensus in defining the com-
ponents of the cough aerosol. Current terminology
linked to cough aerosol and IRD transmission/dispersion
(e.g. particles), are similar to terms used in air quality
studies, where pollutants or “particles” a r em o s t l yc o m -
posed of solid materials and gases generated during
combustion process.
In this article our research group consistently uses the
term droplets instead of particles to define the
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dominates the composition of the airway mucus (~
95%), with solid content filling out the remaining per-
centage. A consensus will enhance our effectiveness in
IRD management and protection by reducing confound-
ing terms. A consensus is also needed to clarify how the
influenza virus is transmitted.
The high proportion of droplets smaller than one
micron (97%), expelled as aerosol in a single cough, are
susceptible to rapid evaporation when released to an
environment with different humidity and temperature
than inside the airways. This supports the probability
that an airborne route of transmission could be a domi-
nant force in the transmission of droplet-spread IRD.
Interestingly, a group of researchers led by Palesi
[46,47], have published several studies indicating that,
using a small mammalian model, a viral infection was
transmitted to animals in different cages connected only
by a tube with no direct contact involved. Airborne dro-
plets, emitted by the infected group of animals, are the
most likely mode of transmission in such a model.
Hence, the contribution of droplets smaller than one
micron in viral transmission merits further investigation.
Data from this study allow us to not only characterize
the cough aerosol, but also to identify outstanding emit-
ters. 10 individuals were categorized as high emitters of
cough droplets. One of the high emitters was beyond
two standard deviations greater than the average num-
ber of droplets expelled when coughing and was consid-
ered as an outlier, and the other nine only one standard
deviation apart from the mean.
Data from our participants indicate that age, sex,
weight, height or corporal mass have no statistically sig-
nificant effect on the aerosol composition in terms of
size and number of droplets, as confirmed by linear cor-
relation assessment (Table 2) and ANOVA tests (Table
5). Results of the ANOVA test including all participants
showed a tendency that did not reach a statistically sig-
nificant difference in the following all droplet size cate-
gories. Excluding the outlier removed the tendency
towards a difference that is statistically significant.
These results coincide with previous findings by Zayas
(MSc Thesis, 1989) that viscoelastic properties, deter-
mined by rheology, from tracheal mucus do not differ in
young and old healthy male/female adults who are non-
smokers, including those mature non-smokers with pul-
monary restrictive diseases [48].
The high emitter outlier was identified as a very fit
athlete who practices high intensity sports. Such physi-
cal activities would very likely have a positive effect on
lung mechanics, hence, allowing for a better lung capa-
city. However, it is tempting to speculate that if such a
person happens to develop influenza they could become
a “super-spreader” due to the high number of droplets
expelled when coughing. Figure 2 illustrates the enor-
mous difference between this outlier and the other par-
ticipants. The same figure also highlights that droplets
smaller than one micron (< 1 μm) clearly dominate over
the rest of the droplets sizes.
Regarding the tri-modal size distribution, the third
size mode at ~251 μm (between 215 - 464 μms i z e )i s
very small in our study. This third mode is of such
small magnitude when compared with the other two
m o d e st h a ti ti so n l ye v i d e n ti na n n e x e dF i g u r e3 . 4 .
Johnson in a recent publication, using a different metho-
dology and technique, also reported a third mode peak-
ing at around 200 μm [49]. We are preparing another
article where we will discuss in more detail similarities
and differences of our method and results from other
teams of researchers working on the same topic. Our
team of researchers is fully convinced that only a multi
and trans-disciplinary collaboration will provide the
optimal strategy to best manage, reduce infection, dis-
ease, and death due to IRD in rich and poor countries
alike.
Another high emitter of cough droplets is a self-iden-
tified long-term (+ 30 years) ex-smoker. Previous studies
found that viscoelastic properties of tracheal mucus
from subjects exposed to tobacco smoke determined by
rheological analysis are different (p < 0.05) with respect
to the non-smoker population [50-53]. The remaining
eight high emitters identified themselves as non-smo-
kers. There was no investigation to verify if they have
had any type of voluntary or involuntary exposure to
tobacco smoke, or to other airborne insults.
Pharmacological and non-pharmacological factors are
capable of disrupting the optimum balance of the physi-
cal properties found in mucus. Compounds that break-
up and lyse the cross-linking binding sites at different
levels of the mucin glycoprotein gel network can subse-
quently affect the natural balance of viscosity and elasti-
city of the airway mucus. Thus, transforming it in a less
cohesive or more watery fluid, facilitating airway mucus
droplet formation. This is an unexplored area that needs
to be addressed.
A literature search yielded no scientific or empiric
information regarding the effect that natural and/or
non-natural compounds may exert on aerosolization of
mucus during respiratory condition treatment. This is
an area that also merits detailed research due to the
wide and common use of these compounds and in light
of recent epidemic-prone and pandemic-prone droplet-
spread IRD. Therefore, it is critical to determine and
grade the effect of both pharmacological and/or non-
pharmacological factors on airway mucus aerosolization.
Seven participants were identified as Low emitters.
Initially, we interpreted this result as a technical issue:
that during the study these participants for some reason
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vented it to cross the measurement zone of the laser
beam. The other possibility we are contemplating is that
these participants may have inherent physical properties
in their airway mucus that makes it more resistant to
break up into droplets when coughing. There may be
other explanations and we are preparing to explore
these in future studies.
Based on the results obtained in this study we are
confident that we have achieved a strategic and critical
step towards optimizing management of droplet-spread
epidemic-prone infectious diseases in the form of a
detailed real-time characterization of the cough aerosol
regarding the size and, more importantly, the number of
droplets expelled when coughing.
The ERS definition of cough does not mention any-
thing about droplets formed and expelled as a direct
result of the interaction of the high-speed airflow with
the layer of airway mucus during the expulsive phase. A
consensus panel report on “managing cough as a defense
mechanism and as a symptom“ [54], endorsed by the
American College of Chest Physician, the American
Thoracic Society, and the Canadian Thoracic Society,
made a detailed, highly clinical description of coughing.
However, it does not discuss anything regarding cough
aerosol droplets as the vehicle of transmission of IRD.
The fact that several of the most prestigious interna-
tional professional organizations dealing with lung
health and/or respiratory diseases, including the Council
of Canadian Academies, are not discussing droplet for-
mation and expulsion during coughing as a critical fac-
tor in IRD transmission and dispersion indicates that
there is a knowledge gap and lack of consensus that
require immediate attention [55-59].
This study provides both scientific support as well as
encouragement to design evidence-based preventative
measures and alternatives in existing technologies to opti-
mize public health practices and personal protection bar-
riers in bioaerosol control to prevent the spread of IRD.
The human cough aerosol model could serve as the foun-
dation for the development of an in-vivo, innovative and
robust bioaerosol assessment tool. This tool could be
quite useful during an IRD outbreak as a point of care
diagnostic test for screening, detecting, and monitoring,
individuals with an acute respiratory infectious medical
condition. Our method yield results in less than five min-
utes, hence would reduce time inconveniences in scenarios
where large amounts of individuals continuously gather;
such as emergency entrances in hospitals, airports, bus/
train stations, etc. By using an evidence-based preventative
screening method, staff working in these scenarios will feel
reassured that they have reliable protection.
This technology will complement and enhance protec-
tion to first responders and frontline health care
workers caring for, and transporting, patients to and
from health care institutions. Furthermore, it will also
protect the general public during IRD outbreak trans-
mitted by droplets via direct, indirect and airborne
route.
Despite the fact that Canada has one of the most
advanced healthcare systems in the world, Canadians’
health remains at risk from droplet-spread IRD. The suc-
cess in handling the SARS crisis was questioned, and the
lesson to be taken from this experience is that Canada
has room to improve in its ability to manage IRD out-
breaks, not unlike most countries worldwide [60].
Our research group is aware that our findings clearly
differ from other studies, but we also are aware that our
findings still need further evaluation before confirmation
of our data and findings. For the human cough aerosol
model to achieve its full potential, a much larger sample
of participants is required; hence ongoing recruitment of
subjects is needed for the foreseeable future to confirm
its value.
In addition, our research group at the Mucophysiology
Laboratory, University of Alberta has been developing a
novel non-vaccine strategy, mucomodulation [44,45],
that has shown the potential to slow or stop the spread
of IRD, potentially saving lives as well as reducing the
burden on resources for healthcare systems in rich and
poor countries alike.
Currently the mucomodulation strategy has evolved
into an ongoing comprehensive program known as The
Edmonton Platform, and will serve as a complement to
the WHO Pandemic Preparedness Plan. This program
will be further detailed in a forthcoming article, how-
ever, it is conceived as the launching ground for meth-
ods and tools of innovative technologies, products,
interventions, and strategies suitable to integrate into a
country’s health system, policies and strategies for IRD
outbreak protection.
Data acquired in this study allowed us to achieve our
main objective by establishing the fundamental basis of
a standard human cough aerosol model. This would
enable us all to acquire better knowledge and under-
standing of the human bioaerosol pattern by best char-
acterizing the number and/or size of droplets
production contained in the cough aerosol that might
open new avenues in epidemic-prone and pandemic-
prone IRD outbreaks preparedness.
Conclusions
We have further characterized quantitatively the pattern,
size, and number of droplets of the most important
mode of person-to-person transmission of IRD: the
cough bioaerosol.
The results from this study strengthen the concept
that cough aerosol contributes to direct, indirect and/or
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Influenza A H1N1 virus. This knowledge may contribute
to limit or eliminate the debate around the main route
of transmission of respiratory infections of known and,
more importantly, of unknown infectious respiratory
pathogens.
The optimal control of droplets contained in the aero-
sol expelled while coughing could be best achieved by
applying an integral approach rather than individual
approach. Therefore, we strongly recommend the imple-
mentation of an integral strategy such as the Edmonton
Platform, which has a potential to become the gold
standard in droplet-spread IRD studies, and a Canadian
contribution to the world for droplet-spread epidemic-
prone, pandemic-prone infectious respiratory disease
control.
In later studies we plan to assess the characterization
of the infectious bioaerosol coming from the external
environment towards the respiratory system of a non-
infected individual, and the effectiveness of novel non-
pharmaceutical procedures. The voluntary cough prac-
ticed by healthy participants in an open bench format
could permit us to determine in the near future the
amount and type of droplets expelled by an individual
infected with Influenza A H1N1 virus or with TB visit-
ing a health care facility.
Additional material
Additional file 1: Appendix 1: Figures portraying the remaining
categories of the size in microns and quantities of open bench
cough droplets in one second. Appendix 2: ANOVA tests of the
remaining categories of the size in microns and quantities of open
bench cough droplets in one second.
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